leadf
logo-loader
viewBiocept Inc

Biocept makes available 10,000 nasopharyngeal specimen collection kits used in coronavirus testing

Collected specimens will be shipped overnight to Biocept's San Diego lab with results returned to ordering physicians within 24 to 48 hours

Biocept Inc - Biocept Inc makes available 10,000 nasopharyngeal specimen collection kits used in testing for the SAR-CoV-2 virus that causes the COVID-19 disease
CEO Nall said the company expects its RT-PCR COVID-19 kits to be available in the third quarter of 2020

Biocept Inc (NASDAQ: BIOC) announced Monday the availability of 10,000 nasopharyngeal specimen collection kits used in the RT-PCR testing for the SAR-CoV-2 virus that causes the COVID-19 disease. 

Collected specimens will be shipped overnight to Biocept's high-complexity, CLIA-certified, CAP-accredited and BSL-2 safety level laboratory in San Diego with results returned to ordering physicians in an estimated 24 to 48 hours, the company said.

"As previously reported, securing specimen collection kits to conduct RT-PCR COVID-19 testing has been challenging both for Biocept and other providers,” said CEO Michael Nall in a statement.

READ: Biocept to relocate corporate offices and lab to new San Diego location

“We have solved our initial supply chain challenge by obtaining the swabs, reagents and other components of these kits, assembling them, and making them available for physician ordering.”

Nall said the company expects the Biocept-developed RT-PCR COVID-19 kits to be available in the third quarter of 2020.

"We are pleased to be offering this testing during the continuing pandemic, with RT-PCR testing providing the most accurate results for detecting active COVID-19 virus," he added. 

Nall said Biocept expanded its relationship with Thermo Fisher Scientific to run the tests on Thermo’s molecular diagnostic platform that has won emergency-use authorization from the US Food and Drug Administration.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: Biocept Inc

Price: 4.32 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $57.86 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Biocept announces Highmark has made a positive coverage determination on...

Biocept (Nasdaq: BIOC) CEO Michael Nall joined Steve Darling from Proactive with news the company has received positive news from Highmark, America’s fourth-largest Blue Cross Shield affiliate. That news being Biocept's Target Selector liquid biopsy assays have been accepted for medical coverage...

on 23/9/20

2 min read